

## Myocardial Ischemia: Global Pipeline Review, H1 2018

PUNE, MAHARASHTRA, INDIA, February 19, 2018 /EINPresswire.com/ --

Myocardial Ischemia

Overview

Lack of blood flow and oxygen to the heart muscle lead to cardiac ischemia, also called myocardial ischemia. The signs and symptoms may include chest pain, typically on the left side of the body (angina pectoris), neck or jaw pain, shoulder or arm pain, and clammy skin, shortness of breath and nausea and vomiting.



Myocardial ischemia can be caused by conditions such as coronary artery disease (atherosclerosis), blood clot, coronary spasm and severe illnesses. The factors that may increase the risk of developing myocardial ischemia include tobacco, diabetes, high blood pressure, high blood cholesterol or triglyceride levels, lack of physical activity, obesity and family history.

Click here for sample report @ <u>https://www.wiseguyreports.com/sample-request/2989075-myocardial-ischemia-pipeline-review-h1-2018</u>

Top Companies mentioned

Angionetics Inc

Bayer AG

Cellmid Ltd

CohBar Inc

Lixte Biotechnology Holdings Inc

NoNO Inc

**Omniox Inc** 

Pathfinder Cell Therapy Inc

Myocardial Ischemia Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Myocardial Ischemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Myocardial Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Myocardial Ischemia - Competitive Analysis

Key players are making innovative developments in Myocardial Ischemia industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Ischemia.

The pipeline guide reviews pipeline therapeutics for Myocardial Ischemia by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Myocardial Ischemia therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Myocardial Ischemia therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Ischemia.

## .Continued

For Detailed Reading Please visit @ <u>https://www.wiseguyreports.com/reports/2989075-myocardial-ischemia-pipeline-review-h1-2018</u>

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

NORAH TRENT Wise Guy Reports +91 841 198 5042 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.